Clinical Studies Search

Protocol Summary


Protocol No.
PSCI-18-090
Prinicipal Investigator
Claxton, David
Phase
Phase II
Age Group
Adult
Scope
National
Secondary Protocol No.
PrE0905
Title
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Objective
To improve the FLT3 mutation negative (evaluated by polymerase chain reaction [PCR])Composite Complete Response (CRc) [includes Complete Response (CR) or CR with incomplete hematologic recovery (CRi)] rate of patients with FLT3 mutated AML who receive gilteritinib compared to those who receive midostaurin in addition to standard therapy with cytarabine and daunorubicin during induction.
Applicable Disease Sites
Myeloid and Monocytic Leukemia
Status
Open
Participating Institutions
Hershey Medical Center